Across TCGA pan-cancer cohorts, ENTPD4 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ENTPD4 data layer compared with 27 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher ENTPD4 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated ENTPD4 expression acts as an unfavorable survival marker, although some lineages such as UCEC and COAD show a favorable association.

UCEC, BRCA, and KIRC are the cancer types where ENTPD4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	II,III,IV	1.000	0.439	.017	32	view →
BRCA	OS	Median	III,IV	0.200	0.833	<.001	30	view →
KIRC	OS	Median	All	0.182	0.805	.003	15	view →
PRAD	DFS	Median	All	0.617	0.886	.013	6	view →
SKCM	DFS	Median	IV	0.036	0.433	<.001	6	view →
COAD	DFS	Median	III,IV	1.000	0.396	.036	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

Exploration

Same gene, other analysis: ENTPD4 tumor-vs-normal RNA expression · all ENTPD4 data types